PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 31626039-7 2020 Moreover, Gen decreased expressions of inducible NO synthase (iNOS) and gp, reduced NO and superoxide anions production, and ameliorated their cytotoxic reaction product, peroxynitrite. Genistein 10-13 nitric oxide synthase 2, inducible Mus musculus 39-60 31626039-7 2020 Moreover, Gen decreased expressions of inducible NO synthase (iNOS) and gp, reduced NO and superoxide anions production, and ameliorated their cytotoxic reaction product, peroxynitrite. Genistein 10-13 nitric oxide synthase 2, inducible Mus musculus 62-66 22819564-0 2013 Genistein accelerates refractory wound healing by suppressing superoxide and FoxO1/iNOS pathway in type 1 diabetes. Genistein 0-9 nitric oxide synthase 2, inducible Mus musculus 83-87 27431618-8 2016 Moreover, genistein supplementation restored NLRP3 inflammasome (NLRP3, ASC and caspase-1) at the basal level and ameliorated both inflammation (TNFalpha, iNOS, COX2 and NFkappaB) and antioxidant defense system (Nrf2, HO-1, GPx, and catalase) during early stage of wound healing in diabetic mice. Genistein 10-19 nitric oxide synthase 2, inducible Mus musculus 155-159 27440533-9 2016 At all tested concentrations, genistein significantly increased iNOS expression in mesenteric artery PVAT (vs. standard chow, P<.001; vs. genistein-enriched, P=.002) and tended to increase iNOS within the aortic PVAT (standard chow, P=.075) compared to the genistein-free group. Genistein 30-39 nitric oxide synthase 2, inducible Mus musculus 64-68 27440533-9 2016 At all tested concentrations, genistein significantly increased iNOS expression in mesenteric artery PVAT (vs. standard chow, P<.001; vs. genistein-enriched, P=.002) and tended to increase iNOS within the aortic PVAT (standard chow, P=.075) compared to the genistein-free group. Genistein 30-39 nitric oxide synthase 2, inducible Mus musculus 192-196 29747742-7 2018 RESULTS: The results showed that genistein exerted inhibitory effects on LPS-induced expressions of cyclooxygenase-2 (COX-2), inducible nitric oxide (iNOS), tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1beta) and interleukin-6 (IL-6). Genistein 33-42 nitric oxide synthase 2, inducible Mus musculus 150-154 24818258-3 2014 Furthermore, genistein alleviated the pro-inflammatory cytokines including tumor necrosis factor-alpha (TNF-alpha) and nitric oxide (NO)/inducible nitric oxide synthase (iNOS) by inhibiting nuclear factor-kappaB (NF- kappaB) activity. Genistein 13-22 nitric oxide synthase 2, inducible Mus musculus 137-168 24818258-3 2014 Furthermore, genistein alleviated the pro-inflammatory cytokines including tumor necrosis factor-alpha (TNF-alpha) and nitric oxide (NO)/inducible nitric oxide synthase (iNOS) by inhibiting nuclear factor-kappaB (NF- kappaB) activity. Genistein 13-22 nitric oxide synthase 2, inducible Mus musculus 170-174 22819564-8 2013 In diabetic wound tissues, the inducible nitric oxide synthase (iNOS) was activated, and genistein administration prevented increased iNOS activity. Genistein 89-98 nitric oxide synthase 2, inducible Mus musculus 134-138 22819564-10 2013 Genistein rescued the delayed wound healing and improved wound angiogenesis in STZ-induced type 1 diabetes in mice, at least in part, by suppression of FoxO1, iNOS activity and oxidative stress. Genistein 0-9 nitric oxide synthase 2, inducible Mus musculus 159-163 12858016-5 2003 To determine signaling molecules contributing to sGITR-induced iNOS production, a specific inhibitor for signal pathway proteins tested showed that PDTC (NF-kappaB) and genistein (tyrosine kinase) inhibited NOS induction significantly, while sodium orthovanadate (tyrosine phosphatase) potentiated NOS expression. Genistein 169-178 nitric oxide synthase 2, inducible Mus musculus 63-67 18476963-9 2008 TK inhibitor genistein inhibited both nNOS and iNOS expression on the membrane of basal keratinocytes, and nuclear translocation of NF-kappaB. Genistein 13-22 nitric oxide synthase 2, inducible Mus musculus 47-51 17108235-9 2007 Interestingly, a JNK inhibitor (SP600125) and another tyrosine kinase inhibitor (genistein) significantly inhibited STAT-1 phosphorylation, suggesting that the LPS-activated JNK pathway and a tyrosine kinase pathway (especially Tyk2) may link to the STAT-1 pathway, which is involved in iNOS induction. Genistein 81-90 nitric oxide synthase 2, inducible Mus musculus 287-291 16284791-4 2006 The G plus IFN-gamma association caused an increase in iNOS promoter activity which was inhibited by pyrrolidine dithiocarbammate (PDTC) at 6 and 24 h as well as by genistein (Gen) and tyrphostine B42 (TB42) at 1 h, inhibitors of NF-kappaB, IRF-1, and STAT-1alpha activation, respectively. Genistein 165-174 nitric oxide synthase 2, inducible Mus musculus 55-59 10811015-5 2000 Herbimycin A and genistein, potent natural inhibitors of protein tyrosine (but not serine/threonine) phosphorylation, block ceramide-induced iNOS and TNF production. Genistein 17-26 nitric oxide synthase 2, inducible Mus musculus 141-145 10704144-3 1999 In contrast, genistein or tyrphostin AG126 also prevented the induction of iNOS protein and activity in J774.2 macrophages elicited by LPS. Genistein 13-22 nitric oxide synthase 2, inducible Mus musculus 75-79 9988718-3 1999 Analysis by transitory transfections showed that LPS, alone or with IFN-gamma, stimulated activity of the murine NOS-2 promoter fragment linked upstream of luciferase and its suppression by PDTC and by the different protein kinase inhibitors, genistein (tyrosine kinase inhibitor), PD98059 (mitogen-actived protein (MAP) kinase kinase inhibitor), and SB 203580 (p38 MAP inhibitor). Genistein 243-252 nitric oxide synthase 2, inducible Mus musculus 113-118 10353257-5 1999 Tyrosine kinase inhibitors (e.g. genistein and tyrphostin AG126) inhibited both TP-induced nitrite and iNOS protein production. Genistein 33-42 nitric oxide synthase 2, inducible Mus musculus 103-107 9387468-4 1996 NMMA, AD as well as Genistein could inhibit the NO production, the activity of iNOS was decreased by both AD and Genistein. Genistein 20-29 nitric oxide synthase 2, inducible Mus musculus 79-83 9096597-8 1997 The protein tyrosine kinase inhibitors such as genistein and tyrphostin reduced IFN-r plus LPS-induced iNOS mRNA expression and NO production. Genistein 47-56 nitric oxide synthase 2, inducible Mus musculus 103-107 9492347-5 1998 Genistein, at low doses, also appeared to attenuate immunohistochemical staining for inducible nitric oxide synthase (iNOS) and nitrotyrosine. Genistein 0-9 nitric oxide synthase 2, inducible Mus musculus 85-116 9492347-5 1998 Genistein, at low doses, also appeared to attenuate immunohistochemical staining for inducible nitric oxide synthase (iNOS) and nitrotyrosine. Genistein 0-9 nitric oxide synthase 2, inducible Mus musculus 118-122 34242900-7 2021 The expression of iNOS was reduced, whereas the expression of M2 macrophage markers was increased in combined treatment of MET and genistein. Genistein 131-140 nitric oxide synthase 2, inducible Mus musculus 18-22 8613229-6 1996 To determine whether a tyrosine kinase-mediated signaling pathway was involved in interleukin action, we used the inhibitor genistein, which blocked interleukin-stimulated nitrites, iNOS protein, and iNOS mRNA. Genistein 124-133 nitric oxide synthase 2, inducible Mus musculus 182-186 8613229-6 1996 To determine whether a tyrosine kinase-mediated signaling pathway was involved in interleukin action, we used the inhibitor genistein, which blocked interleukin-stimulated nitrites, iNOS protein, and iNOS mRNA. Genistein 124-133 nitric oxide synthase 2, inducible Mus musculus 200-204 35498148-9 2022 Flow cytometry analysis indicated that genistein treatment significantly decreased the ratio of M1 macrophages (CD45+/Gr-1-/CD11b+/iNOS+) and increased the ratio of M2 macrophages (CD45+/Gr-1-/CD11b+/Arginase 1+) in the SCI area of SCI mice on the 28th day after being treated with genistein. Genistein 39-48 nitric oxide synthase 2, inducible Mus musculus 131-135